Long-acting injectable buprenorphine – ‘best practice’ opioid agonist therapy for Australian prisoners-Reference-Cited by-同舟云学术

Long-acting injectable buprenorphine – ‘best practice’ opioid agonist therapy for Australian prisoners

Published:2021-12-01 Issue: Volume: Page:103985622110590
ISSN:1039-8562
Container-title:Australasian Psychiatry
language:en
Short-container-title:Australas Psychiatry

Author:

Scott Russ¹^ORCID,Aboud Andrew¹,O’Gorman Thomas²

Affiliation:

1. Prison Mental Health Service, Brisbane, Queensland, Australia

2. Metro North Mental Health Alcohol and Drug Service, Brisbane, Queensland, Australia

Abstract

Objective To consider opioid agonist therapy in prisons. Conclusions Given the substantial risks of substance misuse by prisoners, long-acting injectable buprenorphine should be adopted as ‘best practice’ treatment in Australian prison populations.

Publisher

SAGE Publications

Subject

Psychiatry and Mental health

Link

http://journals.sagepub.com/doi/pdf/10.1177/10398562211059086

Reference32 articles.

1. Substance Use During Imprisonment in Low- and Middle-Income Countries

2. Definitions related to the use of pharmaceutical opioids: Extramedical use, diversion, non-adherence and aberrant medication-related behaviours

3. Longitudinal injecting risk behaviours among people with a history of injecting drug use in an Australian prison setting: The HITS-p study

4. High-risk drug-use practices among a large sample of Australian prisoners

5. The extramedical use and diversion of opioid substitution medications and other medications in prison settings in Australia following the introduction of buprenorphine-naloxone film

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Feasibility and effectiveness of extended-release buprenorphine (XR-BUP) among correctional populations: a systematic review;The American Journal of Drug and Alcohol Abuse;2024-06-28

2. Using the Alcohol, Smoking and Substance Involvement Screening Test to predict substance‐related hospitalisation after release from prison: A cohort study;Addiction;2023-10-19

3. ‘I just thought that was the best thing for me to do at this point’: Exploring patient experiences with depot buprenorphine and their motivations to discontinue;International Journal of Drug Policy;2023-05

4. A prison mental health network in the RANZCP;Australasian Psychiatry;2023-02-07

5. The predictive validity of the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) for moderate‐ to high‐risk cannabis, methamphetamine and opioid use after release from prison;Addiction;2023-02-06